Cohort1: Previous Placebo
|
Administration route |
subcutaneous injection |
Dosage |
Inotersen, 300 mg, weekly, up to 260 weeks |
Pts |
50 |
Age |
Adult, Older_Adult |
Adverse reactions |
2/50(All-cause mortality); 18/50(Cardiac disorders; Eye disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Psychiatric disorders; Renal and urinary disorders; Reproductive system and breast disorders; Vascular disorders) |
References |
PMID:
32343462 |
34355354 |
35799473 |
35908242
|
|
Cohort2: Previous Inotersen
|
Administration route |
subcutaneous injection |
Dosage |
Inotersen, 300 mg, weekly, up to 260 weeks |
Pts |
85 |
Age |
Adult, Older_Adult |
Adverse reactions |
15/85(All-cause mortality); 46/85(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Vascular disorders) |
References |
PMID:
32343462 |
34355354 |
35799473 |
35908242
|
|